看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
* A7 b, o# f0 O5 X7 X7 v ~4 w
5 h+ ?1 P/ {+ p6 n2 o1 T8 |7 i I& ^: }
Currently available feasibility data for possible combination strategies. ; t N* A1 o6 W, n: r8 K
————————————————————————————————
2 v7 h- y6 I/ m; yCombination Feasibility according to preliminary data
; M' p/ D C& Y3 Z——————————————————————————————————
9 \0 }3 }% D) IBevacizumab + sorafenib Yes, reduced dose " s8 Q) z% p( R- U; U$ |) o' Y: \
Bevacizumab + sunitinib† No
' b9 q& ]- G& @4 q4 Q+ D# ?0 ABevacizumab + temsirolimus Yes
8 A! w) E- a2 ?( D! h0 Q3 uBevacizumab + everolimus Yes
* ]* k7 r0 t( P4 S% o# Q* r) E2 Y6 H0 }Sorafenib + sunitinib ?
0 }7 L! P6 a6 t3 H; D+ {Sorafenib + temsirolimus Yes, reduced dose 9 T9 ^7 j6 E; M# t( a/ ?1 D
Sorafenib + everolimus Yes, reduced dose
- ]5 o7 ^9 p% @1 Q4 cSunitinib + temsirolimus† No 5 B h& Y2 y3 N" r/ S* l
Sunitinib + everolimus ?
`( e6 G' j# Z: i zTemsirolimus + everolimus ? % H: v9 F* C6 x( X
————————————————————
* b( \' |5 W' r/ G: o†Led to US FDA warning.
3 h& V* a# [% N( x?: As yet unattempted combination.
( }0 r& s2 |$ k" X: p* e4 h( K |